肿瘤第一线 · 学术知识传播

订阅

MedSci主页 / 所有栏目 / 肿瘤第一线 · 学术知识传播

Overexpression of catalytic subunit M2 in patients with ovarian

2021-11-25 王黎明 王黎明

妇科肿瘤资讯阅读

The formation and growth of tumors are related to the synthesis of the DNA.

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759090, encodeId=6a801e5909058, content=<a href='/topic/show?id=72e713e98c1' target=_blank style='color:#2F92EE;'>#patients#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13798, encryptionId=72e713e98c1, topicName=patients)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956837414446, createdName=hittouch, createdTime=Sun Jul 10 19:19:15 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922107, encodeId=c0e6192210ebf, content=<a href='/topic/show?id=1b8b13e960a' target=_blank style='color:#2F92EE;'>#Patient#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13796, encryptionId=1b8b13e960a, topicName=Patient)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jun 10 05:19:15 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995718, encodeId=3d571995e1846, content=<a href='/topic/show?id=eea918e1288' target=_blank style='color:#2F92EE;'>#With#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18712, encryptionId=eea918e1288, topicName=With)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 15 13:19:15 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649449, encodeId=ba9616494496e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Wed Jul 06 16:19:15 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785936, encodeId=6a6c1e85936a1, content=<a href='/topic/show?id=0b5de17280' target=_blank style='color:#2F92EE;'>#Expression#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7172, encryptionId=0b5de17280, topicName=Expression)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Mar 13 06:19:15 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466122, encodeId=a5df1466122bb, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=199, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sat Nov 27 08:19:15 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-07-10 hittouch

    #patients#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1759090, encodeId=6a801e5909058, content=<a href='/topic/show?id=72e713e98c1' target=_blank style='color:#2F92EE;'>#patients#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13798, encryptionId=72e713e98c1, topicName=patients)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956837414446, createdName=hittouch, createdTime=Sun Jul 10 19:19:15 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922107, encodeId=c0e6192210ebf, content=<a href='/topic/show?id=1b8b13e960a' target=_blank style='color:#2F92EE;'>#Patient#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13796, encryptionId=1b8b13e960a, topicName=Patient)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jun 10 05:19:15 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995718, encodeId=3d571995e1846, content=<a href='/topic/show?id=eea918e1288' target=_blank style='color:#2F92EE;'>#With#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18712, encryptionId=eea918e1288, topicName=With)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 15 13:19:15 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649449, encodeId=ba9616494496e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Wed Jul 06 16:19:15 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785936, encodeId=6a6c1e85936a1, content=<a href='/topic/show?id=0b5de17280' target=_blank style='color:#2F92EE;'>#Expression#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7172, encryptionId=0b5de17280, topicName=Expression)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Mar 13 06:19:15 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466122, encodeId=a5df1466122bb, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=199, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sat Nov 27 08:19:15 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-06-10 ying_wu

    #Patient#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1759090, encodeId=6a801e5909058, content=<a href='/topic/show?id=72e713e98c1' target=_blank style='color:#2F92EE;'>#patients#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13798, encryptionId=72e713e98c1, topicName=patients)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956837414446, createdName=hittouch, createdTime=Sun Jul 10 19:19:15 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922107, encodeId=c0e6192210ebf, content=<a href='/topic/show?id=1b8b13e960a' target=_blank style='color:#2F92EE;'>#Patient#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13796, encryptionId=1b8b13e960a, topicName=Patient)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jun 10 05:19:15 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995718, encodeId=3d571995e1846, content=<a href='/topic/show?id=eea918e1288' target=_blank style='color:#2F92EE;'>#With#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18712, encryptionId=eea918e1288, topicName=With)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 15 13:19:15 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649449, encodeId=ba9616494496e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Wed Jul 06 16:19:15 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785936, encodeId=6a6c1e85936a1, content=<a href='/topic/show?id=0b5de17280' target=_blank style='color:#2F92EE;'>#Expression#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7172, encryptionId=0b5de17280, topicName=Expression)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Mar 13 06:19:15 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466122, encodeId=a5df1466122bb, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=199, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sat Nov 27 08:19:15 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-09-15 cathymary

    #With#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1759090, encodeId=6a801e5909058, content=<a href='/topic/show?id=72e713e98c1' target=_blank style='color:#2F92EE;'>#patients#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13798, encryptionId=72e713e98c1, topicName=patients)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956837414446, createdName=hittouch, createdTime=Sun Jul 10 19:19:15 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922107, encodeId=c0e6192210ebf, content=<a href='/topic/show?id=1b8b13e960a' target=_blank style='color:#2F92EE;'>#Patient#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13796, encryptionId=1b8b13e960a, topicName=Patient)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jun 10 05:19:15 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995718, encodeId=3d571995e1846, content=<a href='/topic/show?id=eea918e1288' target=_blank style='color:#2F92EE;'>#With#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18712, encryptionId=eea918e1288, topicName=With)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 15 13:19:15 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649449, encodeId=ba9616494496e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Wed Jul 06 16:19:15 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785936, encodeId=6a6c1e85936a1, content=<a href='/topic/show?id=0b5de17280' target=_blank style='color:#2F92EE;'>#Expression#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7172, encryptionId=0b5de17280, topicName=Expression)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Mar 13 06:19:15 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466122, encodeId=a5df1466122bb, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=199, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sat Nov 27 08:19:15 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-07-06 nymo

    #SSI#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1759090, encodeId=6a801e5909058, content=<a href='/topic/show?id=72e713e98c1' target=_blank style='color:#2F92EE;'>#patients#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13798, encryptionId=72e713e98c1, topicName=patients)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956837414446, createdName=hittouch, createdTime=Sun Jul 10 19:19:15 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922107, encodeId=c0e6192210ebf, content=<a href='/topic/show?id=1b8b13e960a' target=_blank style='color:#2F92EE;'>#Patient#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13796, encryptionId=1b8b13e960a, topicName=Patient)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jun 10 05:19:15 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995718, encodeId=3d571995e1846, content=<a href='/topic/show?id=eea918e1288' target=_blank style='color:#2F92EE;'>#With#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18712, encryptionId=eea918e1288, topicName=With)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 15 13:19:15 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649449, encodeId=ba9616494496e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Wed Jul 06 16:19:15 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785936, encodeId=6a6c1e85936a1, content=<a href='/topic/show?id=0b5de17280' target=_blank style='color:#2F92EE;'>#Expression#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7172, encryptionId=0b5de17280, topicName=Expression)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Mar 13 06:19:15 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466122, encodeId=a5df1466122bb, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=199, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sat Nov 27 08:19:15 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-03-13 朱睿睿

    #Expression#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1759090, encodeId=6a801e5909058, content=<a href='/topic/show?id=72e713e98c1' target=_blank style='color:#2F92EE;'>#patients#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13798, encryptionId=72e713e98c1, topicName=patients)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956837414446, createdName=hittouch, createdTime=Sun Jul 10 19:19:15 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922107, encodeId=c0e6192210ebf, content=<a href='/topic/show?id=1b8b13e960a' target=_blank style='color:#2F92EE;'>#Patient#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13796, encryptionId=1b8b13e960a, topicName=Patient)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jun 10 05:19:15 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995718, encodeId=3d571995e1846, content=<a href='/topic/show?id=eea918e1288' target=_blank style='color:#2F92EE;'>#With#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18712, encryptionId=eea918e1288, topicName=With)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 15 13:19:15 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649449, encodeId=ba9616494496e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Wed Jul 06 16:19:15 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785936, encodeId=6a6c1e85936a1, content=<a href='/topic/show?id=0b5de17280' target=_blank style='color:#2F92EE;'>#Expression#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7172, encryptionId=0b5de17280, topicName=Expression)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Mar 13 06:19:15 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466122, encodeId=a5df1466122bb, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=199, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sat Nov 27 08:19:15 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-11-27 bbjsj_1981

    #ATA#

    0

相关资讯

祝贺贝伐珠单抗在中国新增两项适应证

2021年11月19日，看到微信《肿瘤医生》公众号中一篇文章，题目是：今日，贝伐珠单抗斩获卵巢癌、宫颈癌两项妇科肿瘤适应证！为中国患者带来新方案。中国国家药品监督管理局批准贝伐珠单抗两项妇科肿瘤适应症

年轻妇女宫颈癌的临床特征和预后

年轻宫颈癌发病呈上升趋势，其原因可能与性传播有关，年轻宫颈鳞癌患者手术时保留卵巢是安全可行的，年轻宫颈癌患者预后差与腺癌比例增高，淋巴结转移率高有关。

原发性输卵管癌30例临床分析

原发性输卵管癌是一种罕见的女性生殖道恶性肿瘤，早期诊断困难，预后差。

Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer

Endometrial cancer (EC) is becoming one of the most common gynecologic malignancies.

SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis

High-risk human papillomavirus oncoproteins E6 and E7 are the major etiological factors of cervical

Expression of microRNA-145,OCT4,and SOX2 in double primary endometrioid endometrial and ovarian carcinomas

CA125对早期卵巢癌的检测灵敏度低，特异性低。